Rapid Growth Within About 15 Months of Official Launch
Third-Party Validation Published in International Journal
Accelerating Global Expansion Through ESC Congress and Overseas Partnerships

ARPI Surpasses 120 Hospitals with Adoption of AI ECG Analysis Solution ‘ECG Buddy’ View original image

Medical AI company ARPI Co., Ltd. (CEO Kim Junghee) announced that its AI ECG analysis solution, 'ECG Buddy,' has been adopted by 120 medical institutions in Korea.


ECG Buddy, which officially launched sales in Korea in April 2025, surpassed 120 adopting institutions in just over one year and three months. In particular, the signing of a supply contract with Severance Hospital—one of Korea's 'Big 5' tertiary general hospitals—signifies ARPI's full-scale entry into the top-tier medical institution market in Korea.


ECG Buddy is a software medical device that analyzes 12-lead ECG images using AI to swiftly provide key rhythm classifications, such as arrhythmia, and quantitative cardiac indicators. Along with approval from Korea’s Ministry of Food and Drug Safety, ARPI has also secured major international certifications, including the European CE MDR, Australia's TGA, Taiwan's TFDA, and approvals in Vietnam and New Zealand, laying the foundation for global expansion.


ARPI has achieved results in international technological validation as well. In 2026, the international journal 'npj Digital Medicine' will publish the results of a multicenter independent external validation study based on data from major U.S. academic medical institutions, providing third-party, developer-independent verification of the solution’s performance.


The adoption of a solution that leverages AI to analyze ECGs instantly and accurately is expected to significantly reduce medical staff workload and lower the risk of misdiagnosis.


CEO Kim Junghee stated, "The fact that 120 hospitals have chosen ECG Buddy demonstrates its real-world value recognized in clinical settings," and added, "Starting with the contract with Severance Hospital, we will expand to more tertiary hospitals and lead ECG interpretation standardization in the global market."


ARPI plans to simultaneously expand supply to tertiary general hospitals in Korea and target overseas markets through partnerships in Europe and the Asia-Pacific region. In August, the company will participate in the ESC Congress to present ECG Buddy to cardiology specialists worldwide.



As ARPI continues to achieve rapid adoption, entry into the Big 5 hospitals, and international academic validation, attention is focusing on what competitiveness it will demonstrate not only in Korea but also in the global AI ECG analysis market.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing